Cargando…
Multi‐omic molecular profiling guide’s efficacious treatment selection in refractory metastatic breast cancer: a prospective phase II clinical trial
This prospective phase II clinical trial (Side Out 2) explored the clinical benefits of treatment selection informed by multi‐omic molecular profiling (MoMP) in refractory metastatic breast cancers (MBCs). Core needle biopsies were collected from 32 patients with MBC at trial enrollment. Patients ha...
Autores principales: | Pierobon, Mariaelena, Robert, Nicholas J., Northfelt, Donald W., Jahanzeb, Mohammad, Wong, Shukmei, Hodge, Kimberly A., Baldelli, Elisa, Aldrich, Jessica, Craig, David W., Liotta, Lance A., Avramovic, Sanja, Wojtusiak, Janusz, Alemi, Farrokh, Wulfkuhle, Julia D., Bellos, Angela, Gallagher, Rosa I., Arguello, David, Conrad, Amber, Kemkes, Ariane, Loesch, David M., Vocila, Linda, Dunetz, Bryant, Carpten, John D., Petricoin, Emanuel F., Anthony, Stephen P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8732340/ https://www.ncbi.nlm.nih.gov/pubmed/34437759 http://dx.doi.org/10.1002/1878-0261.13091 |
Ejemplares similares
-
AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers
por: Abu-Khalaf, Maysa M., et al.
Publicado: (2023) -
Predicting 6-month mortality of patients from their medical history: Comparison of multimorbidity index to Deyo–Charlson index
por: Alemi, Farrokh, et al.
Publicado: (2023) -
Electronic Health Record-Based Screening for Substance Abuse
por: Alemi, Farrokh, et al.
Publicado: (2018) -
Selecting Antidepressants Based on Medical History and Stress Mechanism
por: Min, Hua, et al.
Publicado: (2023) -
Analysis of neuroendocrine clones in NSCLCs using an immuno-guided laser-capture microdissection-based approach
por: Baldelli, Elisa, et al.
Publicado: (2022)